Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 4, 2016, Pages 283-290

  Harlaar, Niels J ^a   Koller, Marjory ^a   de Jongh, Steven J ^a   van Leeuwen, Barbara L ^a   Hemmer, Patrick H ^a   Kruijff, Schelto ^a   van Ginkel, Robert J ^a   Been, Lukas B ^a   de Jong, Johannes S ^a,b   Kats Ugurlu, Gursah ^a   Linssen, Matthijs D ^a   Jorritsma Smit, Annelies ^a   van Oosten, Marleen ^a   Nagengast, Wouter B ^a   Ntziachristos, Vasilis ^c   van Dam, Gooitzen M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; FLUORESCENT DYE;

ADULT; AGED; ARTICLE; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; CYTOREDUCTIVE SURGERY; DEATH; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FLUORESCENCE MICROSCOPY; FORMALIN FIXED PARAFFIN EMBEDDED TISSUE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MALE; MEDICAL PROCEDURES; MOLECULAR FLUORESCENCE GUIDED SURGERY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEPSIS; SPECIMEN ANALYSIS; THROMBOEMBOLISM; TISSUES; CARCINOMA; CLINICAL TRIAL; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; FLUORESCENCE IMAGING; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEUM TUMOR; PROCEDURES; REGIONAL PERFUSION; SECONDARY; THERMOTHERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; CARCINOMA; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; FEASIBILITY STUDIES; FEMALE; FLUORESCENT DYES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; OPTICAL IMAGING; PERITONEAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84996599764     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30082-6     Document Type: Article

References (15)

1. 1 Torre, LA, Bray, F, Siegel, RL, Ferlay, J, Lortet-Tieulent, J, Jemal, A, Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. 2 Koppe, MJ, Boerman, OC, Oyen, WJG, Bleichrodt, RP, Peritoneal carcinomatosis of colorectal origin. Ann Surg 243 (2006), 212–222.
3. 3 Verwaal, VJ, Bruin, S, Boot, H, van Slooten, G, van Tinteren, H, 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15 (2008), 2426–2432.
4. 4 Ihemelandu, CU, McQuellon, R, Shen, P, Stewart, JH, Votanopoulos, K, Levine, EA, Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ann Surg Oncol 20 (2013), 3519–3526.
5. 5 Sugarbaker, PH, Ryan, DP, Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?. Lancet Oncol 13 (2012), e362–e369.
6. 6 Klumpp, BD, Schwenzer, N, Aschoff, P, et al. Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI. Abdom Imaging 38 (2013), 64–71.
7. 7 Van Dam, GM, Themelis, G, Crane, LMA, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nature Medicine 17 (2011), 1315–1319.
8. 8 de Boer, E, Harlaar, NJ, Taruttis, A, et al. Optical innovations in surgery. Br J Surg 102 (2015), e56–e72.
9. 9 Weissleder, R, Ntziachristos, V, Shedding light onto live molecular targets. Nat Med 9 (2003), 123–128.
10. 10 van Oosten, M, Crane, LMA, Bart, J, van Leeuwen, FW, van Dam, GM, Selecting potential targetable biomarkers for imaging purposes in colorectal cancer using target selection criteria (TASC): a novel target identification tool. Transl Oncol 4 (2011), 71–82.
11. 11 de Cuba, EMV, de Hingh, IHJT, Sluiter, NR, et al. Angiogenesis-related markers and prognosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Ann Surg Oncol 23 (2016), 1601–1608.
12. 12 Weele ter, EJ, van Scheltinga, AGTT, Linssen, MD, et al. Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use. Eur J Pharm Biopharm 104 (2016), 226–234.
13. 13 Themelis, G, Yoo, JS, Soh, K-S, Schulz, R, Ntziachristos, V, Real-time intraoperative fluorescence imaging system using light-absorption correction. J Biomed Opt, 14, 2009, 064012.
14. 14 Sugarbaker, PH, Peritonectomy procedures. Ann Surg 221 (1995), 29–42.
15. 15 Kuijpers, AMJ, Aalbers, AGJ, Nienhuijs, SW, et al. Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. World J Surg 39 (2015), 453–460.